Clinical trials
Lexeo is conducting gene therapy clinical trials in:
- Cardiomyopathy associated with Friedreich ataxia (FA)
- Arrhythmogenic cardiomyopathy due to PKP2 (PKP2-ACM)
To learn more about these diseases and the Lexeo's clinical programs, read below.
PROGRAM
LX2006 for Friedreich Ataxia
PROGRAM
LX2020 for Arrhythmogenic Cardiomyopathy due to Plakophilin-2 (PKP2) pathogenic variant
Interested in learning more about our programs or clinical trials? Contact us: clinicaltrials@lexeotx.com
ABOUT LEXEO'S CLINICAL TRIALS
Clinical trials are an important and necessary step in the development of new therapies. These studies research the way a potential treatment, like an investigational gene therapy, will interact with the human body. Clinical trials are conducted in phases, with each phase helping to answer more questions to better understand the treatment and demonstrate if it is safe and effective.
The use of Lexeo's gene therapy candidates described above is investigational. Safety and efficacy have not been established. No investigational therapies have been approved by the U.S. Food and Drug Administration or any other health authority or regulatory agency. There is no guarantee that study participants will receive any benefits. There may be risks and side effects associated with taking part in clinical trials. Participants should discuss with their study doctor about taking part in Lexeo's clinical trials.
Taking part in any of Lexeo's clinical trials is voluntary.
Once you enroll in a trial, you can leave the trial at any time, for any reason.